Please upgrade to Flash 8 or higher.
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity.
Orexigen’s lead combination product candidates targeted for obesity are Contrave® (bupropion SR/naltrexone SR), which has completed Phase III clinical trials, and Empatic™ (zonisamide SR/bupropion SR), which is in the later stages of Phase 2 clinical development.
Product Candidates
Clinical Trials
Our Technology
Latest News
